What has balANZ taught us about balancing ultrafiltration with membrane preservation?

Nephrology Dialysis Transplantation

Volumn 28, Issue 8, 2013, Pages 1971-1974

  Davies, Simon J ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

Biocompatibility; Fluid management; Randomized controlled trial; Solute transport; Ultrafiltration capacity

Indexed keywords

GLUCOSE DEGRADATION PRODUCT; INTERLEUKIN 6;

ANURIA; ARTICLE; AWARENESS; BIOCOMPATIBILITY; CHEMICAL ANALYSIS; CLINICAL EFFECTIVENESS; CONCENTRATION (PARAMETERS); CYTOKINE PRODUCTION; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SOLUTE; TISSUE PRESERVATION; ULTRAFILTRATION;

BIOCOMPATIBILITY; FLUID MANAGEMENT; RANDOMIZED CONTROLLED TRIAL; SOLUTE TRANSPORT; ULTRAFILTRATION CAPACITY;

CELL MEMBRANE PERMEABILITY; DIALYSIS SOLUTIONS; HUMANS; KIDNEY DISEASES; PERITONEAL DIALYSIS; PERITONEUM; ULTRAFILTRATION;

EID: 84884555001     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs594     Document Type: Article

References (24)

1. Johnson DW, Brown FG, Clarke M et al. Biocompatible versus standard peritoneal dialysis fluid-thebalANZ trial. J Am Soc Nephrol 2012; 23: 1097-1107
2. Johnson DW, Brown FG, Clarke M et al. the balANZ Trial Investigators. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ Trial. Perit Dial Int 2012; 32: 497-506
3. Johnson DW, Brown FG, Clarke M et al. on behalf of the balANZ Trial Investigators. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial Transplant 2012; 27: 4445-4453
4. Williams JD, Topley N, Craig KJ et al. Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
5. Davies SJ. Overfill or ultrafiltration? We need to be clear. Perit Dial Int 2006; 26: 449-451
6. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66: 2437-2445
7. Perl J, Huckvale K, Chellar M et al. Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 2009; 4: 121-126.
8. Yang X, Fang W, Bargman JM et al. High peritoneal permeability is not associated with higher mortality or technique failure in patients on automated peritoneal dialysis. Perit Dial Int 2008; 28: 82-92
9. Pecoits-Filho R, Carvalho MJ, Stenvinkel P et al. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26: 53-63
10. Gillerot G, Goffin E, Michel C et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005; 67: 2477-2487
11. Oh KH, Jung JY, Yoon MO et al. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant 2010; 25: 1639-1646
12. Mackenzie R, Holmes CJ, Jones S et al. Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients. Kidney Int 2003;88:S84-S93
13. Davies SJ. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transplant 2009; 24: 2620-2622
14. Cooker LA, Luneburg P, Holmes CJ et al. Bicarbonate/Lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001; 21: S102-S107
15. Lui SL, Yung S, Yim A et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis 2012; 60: 966-975
16. le Poole CY, Welten AG, ter Wee PM et al. A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation. Perit Dial Int 2012; 32: 305-315
17. Opatrna S, Lysak D, Trefil L et al. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2012; 32: 37-44
18. le Poole CY, van Ittersum FJ, Valentijn RM et al. 'NEPP' peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO. Perit Dial Int 2012; 32: 45-54
19. Rabbani N, Thornally PJ. Quantitation of markers of protein damage by glycation, oxidation, and nitration in peritoneal dialysis. Perit Dial Int 2009; 29: S51-S56
20. Jansen MA, Hart AA, Korevaar JC et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-453
21. Konings CJ, Kooman JP, Schonck M et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int 2003; 63: 1556-1563
22. Konings CJ, Kooman JP, Gladziwa U et al. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005; 67: 1190-1191
23. Davies SJ, Garcia Lopez E, Woodrow G et al. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrol Dial Transplant 2008; 23: 2982-2988
24. Tan BK, Chan C, Davies SJ. Achieving euvolemia in peritoneal dialysis patients: a surprisingly difficult proposition. Semin Dial 2010; 23: 456-461